Skip to main content
. 2020 Aug 31;53(1):162–171. doi: 10.4143/crt.2020.704

Fig. 4.

Fig. 4.

Survival outcomes of biliary tract cancer patients according to the density of FoxP3 CD4+ helper T cells. (A, B) Progression-free survival (A) and overall survival (B) of biliary tract cancer patients treated with gemcitabine plus cisplatin according to the density of FoxP3 CD4+ helper T cells in the tumor core, tumor margin, and stroma.